Compare ATOM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | IMUX |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 155.8M |
| IPO Year | 2016 | 2013 |
| Metric | ATOM | IMUX |
|---|---|---|
| Price | $2.98 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | ★ 515.6K | 382.7K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,000.00 | N/A |
| Revenue This Year | $361.54 | N/A |
| Revenue Next Year | $233.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.51 |
| 52 Week High | $12.37 | $17.43 |
| Indicator | ATOM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 24.28 | 36.21 |
| Support Level | $2.25 | $6.35 |
| Resistance Level | $3.51 | $8.60 |
| Average True Range (ATR) | 0.23 | 0.65 |
| MACD | -0.09 | 0.19 |
| Stochastic Oscillator | 4.09 | 46.67 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.